Ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless leg syndrome. Ropinirole hydrochloride tablets are the generic version of GlaxoSmithKline’s Requip tablets. This product will
Accolade is a high-powered 755nm, Q-switched Alexandrite laser for the removal of pigmented lesions. The unique combination of various spot sizes and the laser’s high repetition rates is
Acucela plans to initiate dosing of healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of ACU-02 before the end
The patents provide protection in a market where approximately 18,000 new cases of acute myelogenous leukemia (AML) are diagnosed each year and the trend in overall incidence of
Pipex’s anti-copper product candidate oral tetrathiomolybdate (TTM), a thiomolybdate covered by this notice of allowance, has demonstrated a 40% reduction in insoluble amyloid-beta (p < 0.05), a key
The patent includes pharmaceutical compositions, methods of treatment, and combination kits. The patent applies to the use of Xyfid as well as to a range of methods designed
AmpB is a generic drug that has been in use for approximately 50 years and is considered one of the most effective agents in the treatment of systemic
Based upon recent meetings in Shenzhen, China, it is anticipated that Jade Pharmaceutical (JPI) and Guangzhou Lazon Pharmacy (GLP) will work towards completing the acquisition of GLP by
This open label trial is evaluating the safety and efficacy of Curaxin CBLC102 for use in treating patients with hormone-refractory metastatic prostate cancer. The planned enrollment of 32
As part of the agreement, NextRx will continue to provide Blue Cross of Idaho with pharmacy benefits management services for their individual, group and Medicare Part D members.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.